GFI1B is a transcription factor essential for the regulation of erythropoiesis and megakaryopoiesis, and pathogenic variants have been associated with thrombocytopenia and bleeding. Analysing thrombocytopenic families by whole exome sequencing, we identified a novel GFI1B variant (c.648+5G>A), which causes exon 9 skipping and overexpression of a shorter p32 isoform. We report the clinical data of our patients and critically review the phenotype observed in individuals with different GFI1B variants leading to the same effect on the p32 expression. Since p32 is increased in acute and chronic leukemia cells, we tested the expression level of genes playing a role in various type of cancers, including hematological tumors and found that they are significantly dysregulated, suggesting a potential role for GFI1B in carcinogenesis regulation. Increasing the detection of individuals with GFI1B variants will allow us to better characterize this rare disease and determine whether it is associated with an increased risk of developing malignancies.

Faleschini, M., Papa, N., Morel-Kopp, M., Marconi, C., Giangregorio, T., Melazzini, F., et al. (2022). Dysregulation of oncogenic factors by GFI1B p32: investigation of a novel GFI1B germline mutation. HAEMATOLOGICA, 107(1), 260-267 [10.3324/haematol.2020.267328].

Dysregulation of oncogenic factors by GFI1B p32: investigation of a novel GFI1B germline mutation

Marconi, Caterina;Giangregorio, Tania;Seri, Marco;
2022

Abstract

GFI1B is a transcription factor essential for the regulation of erythropoiesis and megakaryopoiesis, and pathogenic variants have been associated with thrombocytopenia and bleeding. Analysing thrombocytopenic families by whole exome sequencing, we identified a novel GFI1B variant (c.648+5G>A), which causes exon 9 skipping and overexpression of a shorter p32 isoform. We report the clinical data of our patients and critically review the phenotype observed in individuals with different GFI1B variants leading to the same effect on the p32 expression. Since p32 is increased in acute and chronic leukemia cells, we tested the expression level of genes playing a role in various type of cancers, including hematological tumors and found that they are significantly dysregulated, suggesting a potential role for GFI1B in carcinogenesis regulation. Increasing the detection of individuals with GFI1B variants will allow us to better characterize this rare disease and determine whether it is associated with an increased risk of developing malignancies.
2022
Faleschini, M., Papa, N., Morel-Kopp, M., Marconi, C., Giangregorio, T., Melazzini, F., et al. (2022). Dysregulation of oncogenic factors by GFI1B p32: investigation of a novel GFI1B germline mutation. HAEMATOLOGICA, 107(1), 260-267 [10.3324/haematol.2020.267328].
Faleschini, Michela; Papa, Nicole; Morel-Kopp, Marie-Christine; Marconi, Caterina; Giangregorio, Tania; Melazzini, Federica; Bozzi, Valeria; Seri, Mar...espandi
File in questo prodotto:
File Dimensione Formato  
10150-Article Text-74095-2-10-20211228.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 6.16 MB
Formato Adobe PDF
6.16 MB Adobe PDF Visualizza/Apri
2020_267328_FALESCHINI_SUPPL.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 256.74 kB
Formato Adobe PDF
256.74 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/919440
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact